Beta Drugs Ltd
Beta Drugs Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
5 of 5 strong
The short version
Beta Drugs targets 20% to 25% annual sales growth over the next 3-4 years, aiming to more than double sales to around INR 850-900 crores by 2030. Beta Drugs aims to grow sales at 20% to 25% annually over the next 4 years, targeting INR850-900 crores revenue by 2030 (Page 15).
From Beta Drugs Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Beta Drugs targets 20% to 25% annual sales growth over the next 3-4 years, aiming to more than double sales to around INR 850-900 crores by 2030.
- Export revenues are expected to grow at least 50% in the current year with a medium-term target of reaching INR 200-250 crores by FY28.
- Exports are anticipated to contribute about 30% of total revenue by FY30.
- The cosmetology and dermatology division aims for 30%-40% annual growth for the next 3-4 years.
- The newly acquired Nivian IVF/fertility business is expected to grow at 30% annually over the next 3-4 years.
- Beta plans to launch 20-25 new oncology products over the next 3-4 years to drive branded sales growth of 20%-25%.
2 more points from Beta Drugs Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Beta Drugs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Beta Drugs invested around INR45 crores last year across three plants, including land purchase for R&D and corporate office which was later dropped in favor of an office building adjacent to current facilities (Page 9).
- The intermediate plant was acquired for INR9 crores with an additional investment of INR15-17 crores; this plant is expected to commercialize by end of this year (Page 9).
- Total planned capex for the next two years is not expected to exceed INR25 crores, primarily towards the intermediate plant (Page 9).
- No major capex planned beyond that, indicating stable capital expenditure outlook (Page 9).
2 more points from Beta Drugs Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Beta Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As of Q1 FY27, Beta Drugs has around 50% of export orders in hand for the upcoming quarter.
- The company expects to fulfill existing orders and is also anticipating new orders and tenders.
- Pending export tenders that were delayed and missed in FY26 have now been awarded in March 2026, with supplies starting from Q1 FY27.
- These delayed tenders had an estimated revenue impact of INR 20-25 crores.
- The company has laid strategies to focus on other high-margin products amid challenges in Platen sales.
2 more points from Beta Drugs Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Beta Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹94 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Beta Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Arthneeti Pro · Annual
Beta Drugs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Beta Drugs Ltd Q4 FY26 results?
Beta Drugs targets 20% to 25% annual sales growth over the next 3-4 years, aiming to more than double sales to around INR 850-900 crores by 2030. Beta Drugs aims to grow sales at 20% to 25% annually over the next 4 years, targeting INR850-900 crores revenue by 2030 (Page 15).
What is Beta Drugs Ltd share price analysis?
Beta Drugs Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 62.0 with a market cap of ₹2,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Beta Drugs Ltd planning capital expenditure?
Beta Drugs invested around INR45 crores last year across three plants, including land purchase for R&D and corporate office which was later dropped in favor of an office building adjacent to current facilities (Page 9).
Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.